About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:
IP: Santiago Ramon y Cajal Agüeras Collaborators: Josep Tabernero Caturla, Jordi Temprana Salvador, INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization – INGENIO, Ana Mazaltob Oaknin benzaquen, Josep Castellví Vives, Ana Vivancos Prellezo, Raquel Pérez López, Joaquim Mateo Valderrama, Javier Hernandez Losa, Vicente Peg Camara, Irene Sansano Valero Funding agency: Instituto de Salud Carlos III Funding: 80400 Reference: PMP21/00107 Duration: 01/01/2022 - 30/06/2026
IP: Cleofé Romagosa Pérez-Portabell Collaborators: Xavier Martínez Gómez, Ximena Garcia Torres Funding agency: Asociación Española Contra el Cáncer Funding: 270130 Reference: ECAEC222952DEAL Duration: 01/12/2022 - 30/11/2027
IP: Maria Mar Hernandez Guillamon Collaborators: Anna Penalba Morenilla, Jessica Camacho Soriano, Anas Chaachou Charradi, Elena Antima Martinez Saez, Laia Fernandez Resano Funding agency: Instituto de Salud Carlos III Funding: 174845 Reference: AC22/00051 Duration: 01/01/2023 - 30/06/2026
IP: Maria Jose Soler Romeo Collaborators: Alejandra Gabaldon Dominguez, Sara Nuñez Delgado, Oriol Bestard Matamoros, Sheila Bermejo Garcia, Concepció Jacobs Cachá, Elena Isabel Crespo Gimeno Funding agency: Instituto de Salud Carlos III Funding: 246840 Reference: AC22_00029 Duration: 01/01/2023 - 30/06/2026
The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
Check the current rates for the services offered by the Translational Molecular Pathology research group.
Current Rates
PDF 0.25 MB
Rates Anatomia Patologica VHIR 2021
PDF 0.22 MB
